Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congenital myopathies are a clinically and genetically heterogeneous group of disorders characterized by early onset hypotonia, weakness and characteristic, but not pathognomonic, structural abnormalities in muscle fibres. The clinical features overlap with muscular dystrophies, myofibrillar myopathies, neurogenic conditions and congenital myasthenic syndromes. We describe a case of cap myopathy with myasthenic features due to a mutation in the TPM2 gene that responded to anticholinesterase therapy. We also review other published cases of congenital myopathies with neuromuscular transmission abnormalities. This report expands the spectrum of congenital myopathies with secondary neuromuscular transmission defects. The recognition of these cases is important since these conditions can benefit from treatment with drugs enhancing neuromuscular transmission.

Original publication




Journal article


Neuromuscul Disord

Publication Date





1103 - 1110


Acetylcholine receptor, Acetylcholinesterase inhibitors, BIN1, Centronuclear myopathies, Congenital myasthenic syndromes, Congenital myopathies, DNM2, Fibre type disproportion, MTM1, Neuromuscular junction, Neuromuscular transmission, Plectinopathy, RYR1, TPM2, TPM3, Tropomyosin, Adolescent, Cholinesterase Inhibitors, Humans, Male, Muscle, Skeletal, Mutation, Myopathies, Structural, Congenital, Neuromuscular Junction Diseases, Tropomyosin